NEW YORK - Pfizer Inc. is buying rival drugmaker Wyeth in a $68 billion cash-and-stock deal that will increase its revenue by 50 percent, solidify its No. 1 rank in the troubled industry and transform it from a pure pharmaceutical company into a broadly diversified health care giant.
Copyright PHILY - Philly.com
